A Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of CM310 in Adolescent Patients With Atopic Dermatitis
Latest Information Update: 17 Sep 2024
At a glance
- Drugs Stapokibart (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Registrational
- Sponsors KeyMed Biosciences
Most Recent Events
- 18 Jul 2024 New trial record